Linked Life Data

20201778

Source:http://linkedlifedata.com/resource/pubmed/id/20201778

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-3-19
pubmed:abstractText
The present manuscript describes the development of a cell-based reporter transcriptional activation assay for evaluating induction of UGT1A1. A reporter construct (pGL-UGT1A1-Luc) encompassing the proximal promoter (nucleotide -254 to +38) and distal enhancer (-3483 to -3194) regions of the human UGT1A1 gene was generated by PCR cloning, and co-transfected with a previously generated PXR construct (pSG5-PXR) into HepG2 cells. The system was then validated using known ligands of PXR, rifampicin (RIF), clotrimazole (CLOT) sulfinpyrazone (SPZ) and phenobarbital (PB), which produced dose dependent induction of UGT1A1 luciferase activity by 4.4, 5.3, 4.7 and 3.7 fold, respectively, relative to the vehicle control, 0.1 % dimethylsulfoxide (DMSO). Aryl hydrocarbon receptor (AhR) ligands a-naphthoflavone (a-Naph), b-naphthoflavone (b-Naph) and 3-methylchloranthene (3-MC) increased UGT1A1 luciferase activity in a concentration dependent manner resulting in 17.2, 11.3 and 6.1 fold, respectively, at their highest concentrations, suggesting that endogenous AhR is also involved in the regulation of the UGT1A1 reporter construct in HepG2 cells. For comparison with transcriptional regulation of endogenous UGT1A1, 10 mM RIF, 50 mM SPZ, 10 mM CLOT, 4 mM 3-MC, 10 mM b-Naph and 25 mM a-Naph also induced UGT1A1 mRNA in human primary hepatocytes by 2.5, 2.8, 3.2, 3.7, 3.9 and 4.3 fold, respectively. In summary, by co-transfecting the UGT1A1 reporter and PXR constructs into HepG2 cells, we have developed a cellular model for evaluating induction of UGT1A1. Data from the reporter gene assay correlated with that generated in human primary hepatocytes. Based on these data, we suggest that this reporter gene assay can be used as a screening tool in the early stages of drug discovery, to evaluate potential induction of UGT1A1 by new chemical entities and to aid in lead selection and optimization.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1872-3128
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
31-8
pubmed:meshHeading
pubmed-meshheading:20201778-Adult, pubmed-meshheading:20201778-Aged, pubmed-meshheading:20201778-Aged, 80 and over, pubmed-meshheading:20201778-Cloning, Molecular, pubmed-meshheading:20201778-Dose-Response Relationship, Drug, pubmed-meshheading:20201778-Drug Design, pubmed-meshheading:20201778-Enzyme Induction, pubmed-meshheading:20201778-Female, pubmed-meshheading:20201778-Genes, Reporter, pubmed-meshheading:20201778-Glucuronosyltransferase, pubmed-meshheading:20201778-Hep G2 Cells, pubmed-meshheading:20201778-Hepatocytes, pubmed-meshheading:20201778-Humans, pubmed-meshheading:20201778-Ligands, pubmed-meshheading:20201778-Male, pubmed-meshheading:20201778-Middle Aged, pubmed-meshheading:20201778-Pharmaceutical Preparations, pubmed-meshheading:20201778-Promoter Regions, Genetic, pubmed-meshheading:20201778-Receptors, Aryl Hydrocarbon, pubmed-meshheading:20201778-Transcription, Genetic
pubmed:year
2010
pubmed:articleTitle
Development of a UGT1A1 reporter gene assay for induction studies: correlation between reporter gene data and regulation of UGT1A1 in human hepatocytes.
pubmed:affiliation
Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research & Development, Collegeville, Pennsylvania 19426, USA. etaj@wyeth.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Validation Studies